Chronic hepatitis B major triplet is difficult to cure at present. The main treatment method is antiviral therapy, if the use of pegylated interferon alpha 2a treatment, once a week subcutaneous injection, each time 180μg, 48 weeks of treatment at the time of discontinuation of follow-up 24 weeks, 32%-36% of patients can achieve the conversion of major triplet into minor triplet, discontinuation of 3 years of follow-up, 11% of patients can achieve surface antigen clearance, to achieve hepatitis B cure. If oral medication is used, such as oral entecavir or tenofovir, 31% of patients can be converted from major triplets to minor triplets and 13% of patients can achieve surface antigen clearance and hepatitis B cure after 5-8 years of treatment. The current goal of chronic hepatitis B treatment is to maximize long-term inhibition of hepatitis B virus replication, reduce hepatocyte inflammation necrosis and liver fibrosis, and delay or reduce the occurrence of liver failure, cirrhosis decompensation and liver cancer.